Myocardial β-adrenoceptor downregulation in idiopathic dilated cardiomyopathy measured in vivo with PET using the new radioligand (S)-[ 11C]CGP12388

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 32, Issue 4, 2005, Pages 443-447

  De Jong, Richard M ^a   Willemsen, Antoon T M ^a   Slart, Riemer H J A ^a   Blanksma, Paul K ^a   Van Waarde, Aren ^a   Cornel, Jan Hein ^b   Vaalburg, Willem ^a   Van Veldhuisen, Dirk J ^a   Elsinga, Philip H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Location Alkmaar   (Netherlands)

Author keywords

Beta adrenergic receptors; Heart failure; Imaging

Indexed keywords

BETA ADRENERGIC RECEPTOR; CGP 12388; CONTRAST MEDIUM; RADIOLIGAND; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONGESTIVE CARDIOMYOPATHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FEMALE; HEART NERVE; HUMAN; MALE; MEDICAL ASSESSMENT; OBSERVATION; POSITRON EMISSION TOMOGRAPHY; RECEPTOR DENSITY; SAMPLE SIZE;

ADULT; AGED; BENZIMIDAZOLES; CARBON RADIOISOTOPES; CARDIOMYOPATHY, DILATED; DOWN-REGULATION; FEMALE; HEART; HUMANS; LIGANDS; MALE; MIDDLE AGED; MYOCARDIUM; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, ADRENERGIC, BETA; TISSUE DISTRIBUTION;

EID: 17944382949     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-004-1701-z     Document Type: Article

References (22)

1. Port JD, Bristow MR. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mo Cell Cardiol 2001;33:887-905.
2. 2-adrenoceptors in the human heart: properties, function and alterations in chronic heart failure. Pharmacol Rev 1991;43:203-42.
3. De Jong RM, Rhodes CG, Anthonio RL, Willemsen AT, Blanksma PK, Lammertsma AA, et al. Parametric polar maps of regional myocardial beta-adrenoceptor density. J Nucl Med 1999;40:507-12.
4. 2-agonist dosing on human cardiac β-adrenoceptor expression in vivo: comparison with changes in lung and mononuclear leukocyte β-receptors. J Nucl Cardiol 1997;4:532-8.
5. De Jong RM, Blanksma PK, Van Waarde A, van Veldhuisen DJ. Measurement of myocardial β-adrenoceptor density in clinical studies: a role for positron emission tomography? Eur J Nucl Med Mol Imaging 2002;29:88-97.
6. Van Waarde A, Elsinga PH, Doze R Heldoom M, Jaeggi KA, Vaalburg W. A novel β-adrenoceptor ligand for positron emission tomography: evaluation in experimental animals. Eur J Pharmacol 1998;343:289-96.
7. 11C]CGP 12388 and a tracer kinetic model. Eur J Nucl Med Mol Imaging 2002; 29:295-304.
8. 18F]fluoro-CGP 12388) for visualization of β-adrenoceptors with positron emission tomography. J Med Chem 1997; 40:3829-35.
9. 11C]CGP12388 and positron emission tomography. Eur J Pharmacol 2001;433:173-6.
10. Delforge J, Syrota A, Mazoyer BM. Experimental design optimisation: theory and application to estimation of receptor model parameters using dynamic positron emission tomography. Phys Med Biol 1989;34:419-35.
11. Delforge J, Syrota A, Mazoyer BM. Identifiability analysis and parameter identification of an in vivo ligand-receptor model from PET data. IEEE Trans Biomed Eng 1990;37:653-61.
12. Delforge J, Syrota A, Lancon JP, Nakajima K, Loc'h C, Janier M, et al. Cardiac beta-adrenergic receptor density measured in vivo using PET, CGP 12177, and a new graphical method. J Nucl Med 1991;32:739-48.
13. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, et al. Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N Engl J Med 1982;307:205-11.
14. 11C CGP-12177 to assess β-adrenergic receptor concentration in idiopathic dilated cardiomyopathy. Circulation 1993;87:1169-78.
15. Brown L, Deighton NM, Bals S, Sohlmann W, Zerkowski HR, Michel MC, et al. Spare receptors for beta-adrenoceptor-mediated positive inotropic effects of catecholamines in the human heart. J Cardiovasc Pharmacol 1992;19:222-32.
16. Schafers M, Dutka D, Rhodes CG, Lammertsma AA, Hermansen F, Schober O, et al. Myocardial presynaptic and postsynaptic autonomic dysfunction in hypertrophic cardiomyopathy. Circ Res 1998;82:57-62.
17. Choudhury L, Rosen SD, Lefroy DC, Nihoyannopoulos P, Oakley CM, Camici PG. Myocardial beta adrenoceptor density in primary and secondary left ventricular hypertrophy. Eur Heart J 1996;17:1703-9.
18. Rosen SD, Boyd H, Rhodes CG, Kaski JC, Camici PG. Myocardial beta adrenoceptor density and plasma catecholamines in syndrome X. Am J Cardiol 1996;78:37-42.
19. Senior R, Lahiri A. Enhanced detection of myocardial ischemia by stress dobutamine echocardiography utilizing the "biphasic" response of wall thickening during low and high dose dobutamine infusion. J Am Coll Cardiol 1995;26:26-32.
20. De Jong RM, Cornel JH, Crijns HJGM, van Veldhuisen DJ. Abnormal contractile responses during dobutamine stress echocardiography in patients with idiopathic dilated cardiomyopathy. Eur J Heart Fail 2001;3:429-36.
21. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558-69.
22. Gilbert EM, Sandoval A, Larrabee P, Renlund DG, O'Connell JB, Bristow MR. Lisinopril lowers cardiac adrenergic drive and increases beta-receptor density in the failing human heart. Circulation 1993;88:472-80.